Skip to main content

Table 1 Detailed summaries of the enrolled studies

From: The prevalence of people who inject drugs among those with HIV late presentation: a meta-analysis

Authors, year Region Type of study The proportion of PWID with LP among all HIV-infected PWID (95% CI) The proportion of PWID with LP to all HIV-infected patients (95% CI) The odds of LP in PWID compared to MSMs (95% CI) The odds of advanced disease in PWID compared to MSMs(95% CI) Quality score References
Hu et al., 2019 China cross-sectional 55 (52.4–58.4) 1.89 (1.74–2.04) 1.39 (1.2–1.67) 2.06 (1.73–2.45) 7* [17]
Wójcik-Cichy et al., 2018 Poland retrospective 80 (67.57–89.77) 17.37 (12.96–22.55) 3.49 (1.63–7.48)   8* [18]
Brannstrom et al., 2015 Sweden cohort 42.8 (24.46–62.82) 36.3 (18.9–62.5) 1.11 (0.49–2.49)   8* [19]
Wilton et al., 2018 Canada cohort 47.65 (39.41–55.98) 57.3 (45–71.7) 0.94 (0.66–1.34)   8* [20]
Camoni et al. 2013 Italy cohort 59.76 (54.23–65.11) 64.1 (55.7–73.3) 1.86 (1.46–1.67)   8* [21]
Siwak et al., 2019 Poland cross-sectional 66.42 (62.69–70.00) 19.87 (18.23–21.58) 2.02 (1.68–2.42) 2.68 (2.24–3.22) 8* [22]
Sobrino-Vegas et al., 2012 Spain cohort 26.64 (23.08–30.45) 12.31 (10.54–14.26) 0.72 (0.58–0.90)   8* [23]
Op de Coul et al., 2014 Netherlands cohort 78.77 (75.29–81.97) 42.5 (38.8–46.4) 2.53 (2.07–3.09) 2.9 (2.35–3.58) 8* [24]
Vives et al., 2012 Spain cohort 55.7 (51.78–59.74) 13.35 (12.06–14.71) 1.66 (1.36–2.03)   8* [25]
Metallidis et al., 2012 Greece retrospective 2.19 (0.98–4.9) 2.23 (1.02–4.86) 8* [26]